Should Surging Vyjuvek-Driven Earnings Reshape How Krystal Biotech (KRYS) Investors View Its Risk Profile?

• In the past quarter, Krystal Biotech, Inc. reported Q2 2026 net income of US$54.77 million, with basic earnings per share from continuing operations of US$1.85, up from US$38.33 million and US$1.33 a year earlier.
• Over the first half of 2026, net income rose to US$110.70 million and higher per-share earnings underscored the earnings power of Vyjuvek alongside an advancing gene therapy pipeline.
• We’ll now examine how this stronger profitability profile, anchored by Vyjuvek’s contribution, reshapes Krystal Biotech’s existing investment narrative and risk balance.

Outshine the giants: these 17 early-stage AI stocks could fund your retirement.

Krystal Biotech Investment Narrative Recap

To own Krystal Biotech, you need to believe Vyjuvek can support durable profitability while the broader gene therapy pipeline matures. The latest Q2 2026 results highlight stronger earnings, but they do not materially change the core near term catalyst, which remains execution on Vyjuvek’s global rollout. The biggest risk still centers on revenue volatility and margin pressure if patient treatment patterns, pricing, or reimbursement for Vyjuvek become less favorable than the recent profit trajectory suggests.

The recent UK marketing authorization for Vyjuvek is especially relevant alongside these earnings, because it reinforces how much of Krystal’s story now rests on successful international expansion. UK approval, with orphan designation and potential long market exclusivity, supports near term revenue opportunities but also sharpens focus on reimbursement decisions, pricing discussions, and the cost of reaching more dispersed DEB patients, all of which tie directly back into the risk of fluctuating margins and earnings.

Yet behind the stronger earnings, there is a less visible risk around how unpredictable Vyjuvek treatment pauses could affect the stability of returns that investors should be aware of…

Read the full narrative on Krystal Biotech (it’s free!)

Krystal Biotech’s narrative projects $1.0 billion revenue and $552.3 million earnings by 2029.

Uncover how Krystal Biotech’s forecasts yield a $361.67 fair value, a 9% upside to its current price.

Exploring Other Perspectives

While recent profits look strong, the most cautious analysts were already assuming only about US$793.3 million of revenue and US$288.5 million of earnings by 2029, which shows how differently you might view today’s Vyjuvek driven results compared with concerns about rising costs and unpredictable treatment patterns.

Explore 5 other fair value estimates on Krystal Biotech – why the stock might be worth 15% less than the current price!

The Verdict Is Yours

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

Contemplating Other Strategies?

Right now could be the best entry point. These picks are fresh from our daily scans. Don’t delay:

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com